David A. Beebe

5.2k citations

23 papers · 4.5k · 1 hit paper · h-index 17

Impact in

Clinical Biochemistry top 0.5%
- Advanced Glycation End Products research
Endocrinology, Diabetes and Metabolism top 2%
- Natural Antidiabetic Agents Studies

Papers in

Cell Biology 7
- Aldose Reductase and Taurine 7
Endocrinology, Diabetes and Metabolism 6
- Diabetes Treatment and Management 5
- Natural Antidiabetic Agents Studies 2

Co-authors: Peter J. Oates (10 shared papers)Ida Giardino (2 shared papers)Mark A. Yorek (2 shared papers)Yasufumi Kaneda (2 shared papers)Diane Edelstein (2 shared papers)Xue Du (2 shared papers)Takeshi Nishikawa (2 shared papers)Michael Brownlee (2 shared papers)
Journals: Journal of Medicinal Chemistry (8 papers)Bioorganic & Medicinal Chemistry Letters (4 papers)Cellular and Molecular Gastroenterology and Hepatology (2 papers)MedChemComm (1 paper)Journal of Hepatology (1 paper)
Partner nations: United States Germany Japan

In The Last Decade

David A. Beebe

23 papers receiving 4.3k citations

David A. Beebe's Hit Papers

align trajectories log scale

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage 2000 · 3.7k citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2000 Nature

Peers

Countries citing papers authored by David A. Beebe

Since Specialization

Citations

This map shows the geographic impact of David A. Beebe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Beebe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Beebe more than expected).

Fields of papers citing papers by David A. Beebe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Beebe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Beebe. The network helps show where David A. Beebe may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Beebe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Beebe Line = papers co-authored together David A. Beebe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature ·Takeshi Nishikawa, Diane Edelstein, Xue Du, Sho‐ichi Yamagishi, Takeshi Matsumura, Yasufumi Kaneda, Mark A. Yorek, David A. Beebe Hit paper breakdown →	2000	3699
2	X-Ray Crystallographic and Kinetic Studies of Human Sorbitol Dehydrogenase Structure ·Thomas A. Pauly, Jennifer L. Ekstrom, David A. Beebe, Boris A. Chrunyk, Matthew C. Griffor, Ajith V. Kamath, S. Edward Lee, R. Madura	2003	86
3	Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems Cellular and Molecular Gastroenterology and Hepatology ·Trenton T. Ross, Collin Crowley, Anthony Rinaldi, David A. Beebe, Matthew P. Lech, Robert V. P. Martinez, Santos Carvajal‐Gonzalez, Magalie Boucher	2020	81
4	Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle Bioorganic & Medicinal Chemistry Letters ·Jeffrey A. Pfefferkorn, Jihong Lou, Martha L. Minich, Kevin J. Filipski, Mingying He, Ru Zhou, Syed Ahsanuddin Ahmed, John W. Benbow	2009	73
5	A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one Journal of Medicinal Chemistry ·Banavara L. Mylari, Sandra J. Armento, David A. Beebe, Edward L. Conn, James B. Coutcher, Michael S. Dina, Melissa T. O’Gorman, Michael C. Linhares	2003	65
6	Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus MedChemComm ·Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates, John Litchfield, Gary E. Aspnes, Arindrajit Basak, John W. Benbow, Martin A. Berliner	2011	63
7	A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and Congeners Journal of Medicinal Chemistry ·Banavara L. Mylari, Sandra J. Armento, David A. Beebe, Edward L. Conn, James B. Coutcher, Michael S. Dina, Melissa T. O’Gorman, Michael C. Linhares	2005	62
8	Spirolactam-Based Acetyl-CoA Carboxylase Inhibitors: Toward Improved Metabolic Stability of a Chromanone Lead Structure Journal of Medicinal Chemistry ·David A. Griffith, Robert L. Dow, Kim Huard, David J. Edmonds, Scott W. Bagley, Jana Polívková, Dongxiang Zeng, Carmen N. García-Irizarry	2013	43
9	Orally-Effective, Long-Acting Sorbitol Dehydrogenase Inhibitors: Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Novel Heterocycle-Substituted Piperazino-Pyrimidines Journal of Medicinal Chemistry ·Margaret Y. Chu‐Moyer, David A. Beebe, James B. Coutcher, Wesley W. Day, Jiancheng Li, Banavara L. Mylari, Peter J. Oates, R. Matthew Weekly +2 others	2001	41
10	Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK) Journal of Medicinal Chemistry ·Kim Huard, Kay Ahn, Paul A. Amor, David A. Beebe, Kris A. Borzilleri, Boris A. Chrunyk, Steven B. Coffey, Edward L. Conn	2017	41
11	De novo lipogenesis is essential for platelet production in humans Nature Metabolism ·William J. Reagan, Gabriele E. Sonnenberg, Michelle F. Clasquin, Katherine J Hales, Shoh M. Asano, Paul A. Amor, Santos Carvajal‐Gonzalez, Norimitsu Shirai	2020	40
12	Reversible inhibition of estrogen receptor activation by molybdate. Journal of Biological Chemistry ·R. ENZIO MULLER, Abdulmaged M. Traish, David A. Beebe, Herbert H. Wotiz	1982	37
13	Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting Journal of Medicinal Chemistry ·Kim Huard, Aaron C. T. Smith, Gregg D. Cappon, Robert L. Dow, David J. Edmonds, Ayman F. El‐Kattan, William P. Esler, Dilinie P. Fernando	2020	26
14	Sorbitol Dehydrogenase Inhibitors (SDIs): A New Potent, Enantiomeric SDI, 4-[2-1R-Hydroxy-ethyl)-pyrimidin-4-yl]-piperazine-1-sulfonic Acid Dimethylamide Journal of Medicinal Chemistry ·Banavara L. Mylari, Peter J. Oates, David A. Beebe, Nathaniel S. Brackett, James B. Coutcher, Michael S. Dina, William J. Zembrowski	2001	22
15	The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes Metabolism ·Melissa A. Linden, Trenton T. Ross, David A. Beebe, Matthew F. Gorgoglione, Karyn L. Hamilton, Benjamin F. Miller, Barry Braun, William P. Esler	2019	20
16	1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes Bioorganic & Medicinal Chemistry Letters ·Kim Andrews, David A. Beebe, John W. Benbow, David A. Boyer, Shawn D. Doran, Shenping Liu, R. Kirk McPherson, Constantin Neagu	2011	18
17	Nishikawa T, Du Edelstein DXL & Yamagishi S et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature404: 787-790 Takeshi Nishikawa, Diane Edelstein, Xue Du, Satoru Yamagishi, Takeshi Matsumura, Yasufumi Kaneda, Mark A. Yorek, David A. Beebe	2000	17
18	A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action: 1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol Journal of Medicinal Chemistry ·Banavara L. Mylari, Peter J. Oates, William J. Zembrowski, David A. Beebe, Edward L. Conn, James B. Coutcher, Melissa T. O’Gorman, Michael C. Linhares	2002	15
19	GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner Cellular and Molecular Gastroenterology and Hepatology ·Wenshan Wang, Melissa R. Miller, Magalie Boucher, Jessica E. Reynold, Natalie A. Daurio, Dongmei Li, Dinesh K. Hirenallur-Shanthappa, Youngwook Ahn	2023	9
20	SAR and species/stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470,711 Bioorganic & Medicinal Chemistry Letters ·Margaret Y. Chu‐Moyer, David A. Beebe, James B. Coutcher, Wesley W. Day, Jiancheng Li, Peter J. Oates, R. Matthew Weekly +1 other	2002	7

About David A. Beebe

David A. Beebe is a scholar working on Cell Biology, Endocrinology, Diabetes and Metabolism, Organic Chemistry, Cancer Research and Epidemiology, having authored 23 papers that have together received 4.5k indexed citations. Recurring topics across this work include Aldose Reductase and Taurine (7 papers), Synthesis and biological activity (5 papers), Diabetes Treatment and Management (5 papers), Liver Disease Diagnosis and Treatment (4 papers), Carbohydrate Chemistry and Synthesis (3 papers), Cancer, Lipids, and Metabolism (3 papers), Nitric Oxide and Endothelin Effects (2 papers) and Natural Antidiabetic Agents Studies (2 papers). The work is most often cited by research in Clinical Biochemistry (459 citations), Endocrinology, Diabetes and Metabolism (681 citations), Biochemistry (267 citations), Nephrology (367 citations) and Physiology (824 citations). David A. Beebe has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Peter J. Oates, Ida Giardino, Mark A. Yorek, Yasufumi Kaneda, Diane Edelstein, Xue Du, Takeshi Nishikawa, Michael Brownlee, Takeshi Matsumura and Sho‐ichi Yamagishi. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Cellular and Molecular Gastroenterology and Hepatology, MedChemComm and Journal of Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

David A. Beebe

Impact in

Papers in i

In The Last Decade

David A. Beebe

David A. Beebe's Hit Papers

Peers

Countries citing papers authored by David A. Beebe

Fields of papers citing papers by David A. Beebe

All Works

About David A. Beebe

Explore authors with similar magnitude of impact

Papers in